Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | A real-world analysis of belantamab mafodotin in patients with R/R multiple myeloma

In this video, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, briefly summarizes a real-world analysis which investigated the safety and efficacy of belantamab mafodotin in the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Dr Landgren highlights some of the findings from this study, including safety information, response rates of patients, and ocular adverse events, and the importance of conducting real-world analyses on newly approved drugs. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.